<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31344020</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1941-5923</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Jul</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of case reports</Title>
          <ISOAbbreviation>Am J Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antisynthetase Syndrome and Autoantibodies: A Literature Review and Report of 4 Cases.</ArticleTitle>
        <Pagination>
          <StartPage>1094</StartPage>
          <EndPage>1103</EndPage>
          <MedlinePgn>1094-1103</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.12659/AJCR.916178</ELocationID>
        <Abstract>
          <AbstractText>BACKGROUND With the advent and advancement of autoantibodies, there has been progress in the diagnosis, prognosis, and treatment of rheumatologic diseases. Antisynthetase syndrome (ASS) is a great example of a disease that initially was described as arthritis, myositis, interstitial lung disease, mechanic's hands, Raynaud's phenomenon, and fever in the presence of the anti-JO-1 antibody, but nowadays it presents with a different spectrum related to new antibodies. CASE REPORT We describe 4 patients with antisynthetase syndrome who were diagnosed with antibodies specific for myositis associated with different clinical findings. All patients responded to immunosuppressive therapy, and rituximab was the most used. CONCLUSIONS It is necessary to search for specific autoantibodies related to the syndrome in suspected clinical cases and in other rheumatological diseases refractory to the usual treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Marin</LastName>
            <ForeName>Flávia Luiza</ForeName>
            <Initials>FL</Initials>
            <AffiliationInfo>
              <Affiliation>Postgraduate Program in Pathophysiology in Medical Clinic, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampaio</LastName>
            <ForeName>Henrique Pereira</ForeName>
            <Initials>HP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Division of Medical Clinic, Section of Medicine, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>07</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Case Rep</MedlineTA>
        <NlmUniqueID>101489566</NlmUniqueID>
        <ISSNLinking>1941-5923</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VB0R961HZT</RegistryNumber>
          <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
          <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537778">Antisynthetase syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="N">Myositis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of interest:</b> None declared. <b>Conflict of interest</b>. None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31344020</ArticleId>
        <ArticleId IdType="pmc">PMC6676984</ArticleId>
        <ArticleId IdType="doi">10.12659/AJCR.916178</ArticleId>
        <ArticleId IdType="pii">916178</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cavagna L, Nuño L, Scirè CA, et al. AENEAS (American, European Network of Antisynthetase Syndrome) collaborative group  Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study. Medicine (Baltimore) 2015;94(32):e1144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4616698</ArticleId>
            <ArticleId IdType="pubmed">26266346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirrakhimov AE. Antisynthetase syndrome: A review of etiopathogenesis, diagnosis and management. Curr Med Chem. 2015;22(16):1963–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25973980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas-Serrano J, Herrera-Bringas D, Mejía M, et al.  Prognostic factors in a cohort of antisynthetase syndrome (ASS): Serologic profile is associated with mortality in patients with interstitial lung disease (ILD) Clin Rheumatol. 2015;34:1563–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26219488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hervier B, Devilliers H, Stanciu R, et al.  Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;(12):210–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22771754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Li S, Yang H, et al.  Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017;47(7):1051–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28461650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wernham M, Montague SJ. Mechanic’s hands and hiker’s feet in antisynthetase syndrome. CMAJ. 2017;189(44):E1365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5675544</ArticleId>
            <ArticleId IdType="pubmed">29109211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hervier B, Meyer A, Dieval C, et al.  Pulmonary hypertension in antisynthetase syndrome: Prevalence, aetiology and survival. Eur Respir J. 2013;42:1271–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23397301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Gay MA, Montecucco C, Selva-O’Callaghan A, et al.  Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clin Exp Rheumatol. 2018;36(1):44–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28770709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hochberg MC, Silman AJ, Smolen JS, et al.   Rheumatology. 6th ed. Philadelphia: Elsevier; 2015. Connective tissue disorders; pp. 1224–54.</Citation>
        </Reference>
        <Reference>
          <Citation>Hallowell RW, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: Recent advances. Curr Opin Rheumatol. 2014;26(6):684–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25203119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi E, Uruha A, Suzuki S, et al.  Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 2017;74(8):992–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710328</ArticleId>
            <ArticleId IdType="pubmed">28586844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibilia J, Chatelus E, Meyer A, et al.   L’utilité des auto-anticorps. Vol. 39. Presse Med, Elsevier; 2010. Comment faire le diagnostic et mieux comprendre les myopathies inflammatoires? pp. 1010–25. [in French]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20655695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dellavance A, Júnior AG, Nuccitelli B, et al.  3º Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2 (FAN). Recomendações para padronização do ensaio depesquisa de autoanticorpos em células HEp-2, controle de qualidade e associações clínicas. Rev Bras Reumatol. 2009;49(2):89–109. [in Portuguese]</Citation>
        </Reference>
        <Reference>
          <Citation>Souza FHC. Autoanticorpos em miopatias autoimunes. Rev Paul Reumatol. 2017;16(4):12–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Satoh M, Tanaka S, Ceribelli A, et al.  A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52(1):1–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5828023</ArticleId>
            <ArticleId IdType="pubmed">26424665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie I, Josse S, Hatron PY, et al.  Interstitial lung disease in anti-jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013;65(5):800–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23203765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hengstman GJD, Ter Laak HJ, Vree Egberts WTM, et al.  Antisignal recognition particle autoantibodies: Marker of a necrotizing myopathy. Ann Rheum Dis. 2006;65:1635–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1798474</ArticleId>
            <ArticleId IdType="pubmed">16679430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picard C, Thierry Vincent T, Lega JC, et al.   Immunol Res. New York: Springer; 2016. Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: A multicentric study.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26744256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musset L, Allenbach Y, Benveniste O, et al.  Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016;15(10):983–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27491568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albayda J, Christopher-Stine L. Identifying statin-associated autoimmune necrotizing myopathy. Cleve Clin J Med. 2014;81(12):736–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25452351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al.  Disease-specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75(4):696–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4699257</ArticleId>
            <ArticleId IdType="pubmed">25714931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghillani P, André C, Toly C, et al.  Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: Results of a multicentric study. Autoimmun Rev. 2011;(10):509–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21447407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefèvre G, Meyer A, Launay D, et al.  Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology (Oxford) 2015;54:927–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25349440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer A, Lefevre G, Bierry G, et al.  Antisynthetase syndrome, ACPA are associated with severe and erosive arthritis – An overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine (Baltimore) 2015;94(20):e523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4602869</ArticleId>
            <ArticleId IdType="pubmed">25997035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrisset J, Johnson C, Rich E, et al.  Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27102182</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
